Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL639043 | 0.88 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL639011 | 0.87 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL639691 | 0.84 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL4417922 | 0.83 | P2RX3 (0.73) | P2RX3P2RX2 | |
| SCHEMBL639618 | 0.82 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL638684 | 0.81 | P2RX3 (0.72) | P2RX3P2RX2 | |
| SCHEMBL639182 | 0.79 | P2RX3 (0.69) | P2RX3P2RX2 | |
| SCHEMBL3657979 | 0.78 | P2RX3 (0.65) | P2RX3P2RX2 | |
| SCHEMBL3662324 | 0.77 | P2RX3 (0.65) | P2RX3P2RX2 | |
| SCHEMBL404572 | 0.77 | P2RX3 (0.63) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119644-B2 | Thiadiazole-substituted arylamides as P2X3 and P2X2/3 antagonists | Roche Palo Alto LLP (US) | 2012-02-21 | — | — | US | claimed |
| US-20170081320-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170081320-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-23 | — | — | US | disclosed |
| US-9173861-B2 | Thiadiazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2015-11-03 | — | — | US | disclosed |
| US-9173861-B2 | Thiadiazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2379518-B1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2014-05-07 | — | — | EP | disclosed |
| US-20120122886-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI (CN) | 2012-05-17 | — | — | US | disclosed |
| US-20120122886-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI (CN) | 2012-05-17 | — | — | US | disclosed |
| US-8119644-B2 | Thiadiazole-substituted arylamides as P2X3 and P2X2/3 antagonists | Roche Palo Alto LLP (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119644-B2 | Thiadiazole-substituted arylamides as P2X3 and P2X2/3 antagonists | Roche Palo Alto LLP (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119644-B2 | Thiadiazole-substituted arylamides as P2X3 and P2X2/3 antagonists | Roche Palo Alto LLP (US) | 2012-02-21 | — | — | US | disclosed |
| CN-102245586-A | Thiadiazole-substituted arylamides | HOFFMANN LA ROCHE | 2011-11-16 | — | — | CN | disclosed |
| EP-2379518-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010069794-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010069794-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-24 | — | — | WO | disclosed |
| US-20100152203-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI | 2010-06-17 | — | — | US | disclosed |
| US-20100152203-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI | 2010-06-17 | — | — | US | disclosed |
| US-20100152203-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122886-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885 |
| US-20170081320-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885 |
| US-20100152203-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.